What’s the Difference Between Mounjaro®, Ozempic®, and Wegovy®?

What Is Mounjaro®?

Mounjaro® (tirzepatide) is a once-weekly injectable medication developed to help manage blood sugar levels in adults with type 2 diabetes. Unlike Ozempic® and Wegovy®, which contain the GLP-1 receptor agonist semaglutide, Mounjaro® activates both GLP-1 and GIP receptors, two hormonal pathways that may influence insulin secretion and blood sugar control.

Key Characteristics of Mounjaro®:

• Active ingredient: Tirzepatide
  
• Mechanism: Dual GIP and GLP-1 receptor agonist
  
• Approved use: Type 2 diabetes
  
• Not approved for weight loss

In studies such as the SURPASS clinical trial series, Mounjaro® demonstrated significant effects on A1C and body weight among participants with type 2 diabetes. However, more research is ongoing to determine its long-term role in chronic weight management.

‍

What Is Ozempic®?

Ozempic® (semaglutide) is another once-weekly GLP-1 receptor agonist used in adults with type 2 diabetes to improve glycemic control. It is not FDA-approved for weight loss.

Key Characteristics of Ozempic®:

• Active ingredient: Semaglutide
  
• Mechanism: GLP-1 receptor agonist
  
• Approved use: Type 2 diabetes
  
• Not approved for weight loss
  
  

Although Ozempic® is only FDA-approved for the treatment of type 2 diabetes, some individuals have reported weight changes during use. These observations may be linked to semaglutide’s activation of the GLP-1 receptor pathway, which is believed to influence appetite regulation and caloric intake. In a 2021 study published in The Lancet, adults receiving semaglutide 2.4 mg, the dosage used in Wegovy® , which is higher than the doses used in Ozempic®, experienced substantial weight reductions when combined with lifestyle interventions. While this study focused on Wegovy®, it has contributed to growing clinical interest in the GLP-1 pathway’s potential role in metabolic health.

Licensed healthcare providers on the Eden platform evaluate each individual’s health history before determining if semaglutide-based treatment is appropriate.

‍

{{primary-cta}}

‍

What Is Wegovy®?

Wegovy® is also a semaglutide-based injectable medication, but unlike Ozempic®, it is FDA-approved for chronic weight management in adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as hypertension or type 2 diabetes.

Key Characteristics of Wegovy®:

• Active ingredient: Semaglutide (at a higher dose than Ozempic®)
  
• Mechanism: GLP-1 receptor agonist
  
• Approved use: Chronic weight management
  
• Dosing: Higher than Ozempic®, generally starting at 0.25 mg and increasing to 2.4 mg weekly
  
  

Clinical studies such as the STEP trials have demonstrated the effectiveness of Wegovy® in supporting weight reduction when combined with lifestyle interventions like diet and exercise.

‍

Comparing Ingredients and Mechanisms

While Mounjaro®, Ozempic®, and Wegovy® are all injectable treatments administered weekly, their pharmacological profiles differ:

‍

‍

Note: This table is for educational purposes and does not replace medical advice. Final treatment decisions should be made with a licensed healthcare provider.

These differences can help licensed healthcare providers determine which, if any, medication may be appropriate based on a patient’s health goals and medical profile.

‍

How Patients Gain Access to These Medications

Eden is a digital health platform that connects adults with licensed healthcare providers and state-licensed compounding pharmacies. Eden does not manufacture medications or practice medicine. Instead, the platform offers a streamlined experience that allows patients to:

• Complete an online health intake form
  
• Connect with a licensed healthcare provider for a consultation
  
• Receive guidance on appropriate treatment options
  
• Medications, when prescribed, are filled by state-licensed compounding pharmacies

This model supports better access to personalized care without requiring patients to visit a clinic in person.

‍

{{primary-cta}}

‍

What to Discuss With a Licensed Healthcare Provider

If you're curious about any of these medications, here are a few questions to consider asking during a consultation:

1. What are the potential risks and benefits of each option?
   
2. Is one medication more appropriate for my metabolic health goals?
   
3. How do these medications interact with my current prescriptions or conditions?
   
4. What kind of follow-up or monitoring would be required?
   
   

Each of these medications may affect individuals differently, and consultation with a licensed provider is the only way to determine whether treatment is appropriate.

‍

Conclusion

While Mounjaro®, Ozempic®, and Wegovy® share similarities in form and frequency of use, they are approved for different purposes and contain different active compounds. Wegovy® is currently the only one of the three approved by the FDA for weight management. Mounjaro® and Ozempic® are approved for managing type 2 diabetes but are being explored in ongoing research for broader metabolic benefits.

Licensed healthcare providers on the Eden platform evaluate each individual's health history before determining whether any of these medications are appropriate as part of a personalized care plan. If you are considering your options, a professional consultation is the safest and most effective place to start.

‍